Liu Tian-Hao, Zhang Chen-Yang, Zhang Hang, Jin Jing, Li Xue, Liang Shi-Qiang, Xue Yu-Zheng, Yuan Feng-Lai, Zhou Ya-Hong, Bian Xiu-Wu, Wei Hong
Yu-Yue Pathology Scientific Research Center Chongqing China.
Department of Pathology Army Medical University Chongqing China.
Imeta. 2024 May 7;3(3):e199. doi: 10.1002/imt2.199. eCollection 2024 Jun.
The drug response phenotype is determined by a combination of genetic and environmental factors. The high clinical conversion failure rate of gene-targeted drugs might be attributed to the lack of emphasis on environmental factors and the inherent individual variability in drug response (IVDR). Current evidence suggests that environmental variables, rather than the disease itself, are the primary determinants of both gut microbiota composition and drug metabolism. Additionally, individual differences in gut microbiota create a unique metabolic environment that influences the in vivo processes underlying drug absorption, distribution, metabolism, and excretion (ADME). Here, we discuss how gut microbiota, shaped by both genetic and environmental factors, affects the host's ADME microenvironment within a new evaluation system for drug-microbiota interactions. Furthermore, we propose a new top-down research approach to investigate the intricate nature of drug-microbiota interactions in vivo. This approach utilizes germ-free animal models, providing foundation for the development of a new evaluation system for drug-microbiota interactions.
药物反应表型由遗传和环境因素共同决定。基因靶向药物较高的临床转化失败率可能归因于对环境因素的忽视以及药物反应固有个体变异性(IVDR)。目前的证据表明,环境变量而非疾病本身是肠道微生物群组成和药物代谢的主要决定因素。此外,肠道微生物群的个体差异创造了独特的代谢环境,影响药物吸收、分布、代谢和排泄(ADME)的体内过程。在此,我们讨论在药物-微生物群相互作用的新评估系统中,受遗传和环境因素塑造的肠道微生物群如何影响宿主的ADME微环境。此外,我们提出一种新的自上而下的研究方法,以研究体内药物-微生物群相互作用的复杂本质。这种方法利用无菌动物模型,为开发药物-微生物群相互作用的新评估系统提供基础。